The Conversation (0)
GlaxoSmithKline plc (NYSE:GSK) and Theravance, Inc. (NASDAQ:THRX) announced that Anoro™ Ellipta® (umeclidinium and vilanterol inhalation powder) is now available to retail pharmacies in the US. Anoro™ Ellipta® is for the maintenance treatment of chronic obstructive pulmonary disease.
GlaxoSmithKline plc (NYSE:GSK) and Theravance, Inc. (NASDAQ:THRX) announced that Anoro™ Ellipta® (umeclidinium and vilanterol inhalation powder) is now available to retail pharmacies in the US. Anoro™ Ellipta® is for the maintenance treatment of chronic obstructive pulmonary disease.
As quoted in the press release:
Anoro Ellipta is a combination anticholinergic/long-acting beta2-adrenergic agonist (anticholinergic/LABA) indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema. Anoro Ellipta is not indicated for the relief of acute bronchospasm or for the treatment of asthma. The FDA-approved strength is umeclidinium/vilanterol 62.5/25mcg.
Click here to read the GlaxoSmithKline (NYSE:GSK) press release
